Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 3 | Unknown | — |
The patient vomited up third capsule of Vivotif; Case reference number US-BN-2025-000857 is a spontaneous case initially received from nurse via agency (reference number: USBAV25-0894) on 22-Apr-2025 and concerns female patient of unspecified age. The patient's medical history and concomitant medication details were not provided. On an unspecified date, the patient took the first dose of Vivotif (batch number: unknown) unknown route, dose, for unknown indication. On an unspecified date, unknown of time after dose, the patient took the second dose of Vivotif (batch number: unknown) unknown route and dose. On an unspecified date, unknown of time after first dose, the patient took the third dose of Vivotif (batch number: unknown) unknown route and dose. On an unspecified date, unknown of time after third dose, the patient vomited up third capsule. At the time of the initial report, it was unknown if the patient recovered from the event 'vomiting of medication'. The reporter assessed event of 'vomiting of medication' as non-serious and does not provide the causality assessment to Vivotif. No further information was provided.; Reporter's Comments: A female patient of unspecified age vomited up third capsule of Vivotif on an unspecified date, an unknown amount of time after the patient took the third dose of Vivotif for unknown indication. Vomiting is listed and expected for Vivotif per CCDS v8 and USPI. The patient's medical history and concomitant medication details were not provided. The outcome was unknown. Considering implied temporal relationship, known vaccine safety profile and since the contributory role of the suspect vaccine cannot be excluded, the reported event has been considered as related to Vivotif. This case is considered as non-serious.; Sender's Comments: A female patient of unspecified age vomited up third capsule of Vivotif on an unspecified date, an unknown amount of time after the patient took the third dose of Vivotif for unknown indication. Vomiting is listed and expected for Vivotif per CCDS v8 and USPI. The patient's medical history and concomitant medication details were not provided. The outcome was unknown. Considering implied temporal relationship, known vaccine safety profile and since the contributory role of the suspect vaccine cannot be excluded, the reported event has been considered as related to Vivotif. This case is considered as non-serious.
Comments: None.